On Monday, Agios Pharmaceuticals Inc (NASDAQ: AGIO) was 4.19% up from the session before settling in for the closing price of $32.19. A 52-week range for AGIO has been $20.96 – $62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.91% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 280.76%. With a float of $55.14 million, this company’s outstanding shares have now reached $57.02 million.
In an organization with 383 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 76.16%, operating margin of -1238.1%, and the pretax margin is 2212.98%.
Agios Pharmaceuticals Inc (AGIO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Agios Pharmaceuticals Inc stocks. The insider ownership of Agios Pharmaceuticals Inc is 3.32%, while institutional ownership is 104.74%. The most recent insider transaction that took place on Jan 03 ’25, was worth 89,279. Before that another transaction happened on Dec 11 ’24, when Company’s Director sold 200 for $46.28, making the entire transaction worth $9,256. This insider now owns 15,483 shares in total.
Agios Pharmaceuticals Inc (AGIO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 280.76% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
You can see what Agios Pharmaceuticals Inc (AGIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 58.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.37, a number that is poised to hit -1.69 in the next quarter and is forecasted to reach -6.13 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was inferior than the volume of 1.26 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 21.75%. Additionally, its Average True Range was 2.63.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 6.35%, which indicates a significant decrease from 15.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.35% in the past 14 days, which was higher than the 64.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.59, while its 200-day Moving Average is $42.31. However, in the short run, Agios Pharmaceuticals Inc’s stock first resistance to watch stands at $34.59. Second resistance stands at $35.64. The third major resistance level sits at $36.80. If the price goes on to break the first support level at $32.38, it is likely to go to the next support level at $31.22. Assuming the price breaks the second support level, the third support level stands at $30.17.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
There are 57,030K outstanding shares of the company, which has a market capitalization of 1.93 billion. As of now, sales total 26,820 K while income totals -352,090 K. Its latest quarter income was 8,960 K while its last quarter net income were 947,920 K.
